Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2022
Drug industry says EMA’s PRIME scheme useful but could be improved
14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate ...
Posted by Michael Wonder on 03 Mar 2022
PhRMA Statement on the State of the Union Address
1 March 2022 - The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the ...
Posted by Michael Wonder on 25 Feb 2022
MAP offers new online pathway for accessing cancer treatments
25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...
Posted by Michael Wonder on 22 Feb 2022
Does the DoH favour some pharmaceutical companies over others?
23 February 2022 - Some interesting insights from version 1 of the agenda for the May 2022 PBAC (intracycle) meeting. ...
Posted by Michael Wonder on 21 Feb 2022
COVID-19 pandemic sends clear message that Australia must value the long-term health of all Australians
21 February 2022 - Medicines Australia is warning that Australia must act now to ensure that our health system is ...
Posted by Michael Wonder on 31 Jan 2022
Drug makers raised prices by 6.6% on average early this year
30 January 2022 - The companies kept most increases in the single digits for another year as Congress explores measures to ...
Posted by Michael Wonder on 31 Jan 2022
Fables and misperceptions about drug makers and drug pricing are misleading customers about the value the industry provides
27 January 2022 - In my last column, I discussed the need for the pharmaceutical industry to more publicly highlight the ...
Posted by Michael Wonder on 30 Jan 2022
Medicines regulator pilot probes pharma delays in market launches
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...
Posted by Michael Wonder on 28 Jan 2022
Australians deserve fast access to the latest medicines, vaccines and treatments
28 January 2022 - Medicines Australia recommends the Australian Government delivers a plan to shorten the time that patients wait ...
Posted by Michael Wonder on 14 Dec 2021
mRNA manufacturing facility will deliver long term health benefits for Australians
14 December 2021 - Medicines Australia welcomes the announcement that Australia will manufacture mRNA vaccines in a deal struck with ...
Posted by Michael Wonder on 13 Dec 2021
Forecast 2 for the 2021 rebate from side agreements
13 December 2021 - In a new report to the government, TLV forecasts that the pharmaceutical companies will pay approximately ...
Posted by Michael Wonder on 11 Dec 2021
‘All I want for Christmas’ is higher prices: Congressional report accuses pharma of manipulating Americans for profit
10 December 2021 - It was the day before Christmas in 2015 and a senior director of national accounts at ...
Posted by Michael Wonder on 26 Nov 2021
Additional insights from the agenda for the March 2022 PBAC meeting
26 November 2021 - More insights from the MAESTrO Team. ...
Posted by Michael Wonder on 25 Nov 2021
Drugmakers gear up for price restrictions in Biden’s legislative agenda
25 November 2021 - Industry potentially faces significant expansion of government regulation despite success in watering down Democratic proposals. ...
Posted by Michael Wonder on 03 Nov 2021
PhRMA statement on Democrats' drug pricing deal in reconciliation package
2 November 2021 - The following can be attributed to PhRMA President and CEO Stephen J. Ubl. ...